Four-repeat tauopathies and late-onset psychiatric disorders: Etiological relevance or incidental findings?
argyrophilic grain disease
bipolar disorder
corticobasal degeneration
progressive supranuclear palsy
psychotic disorder
Journal
Neuropathology : official journal of the Japanese Society of Neuropathology
ISSN: 1440-1789
Titre abrégé: Neuropathology
Pays: Australia
ID NLM: 9606526
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
16
04
2022
received:
20
02
2022
accepted:
24
04
2022
pubmed:
2
7
2022
medline:
4
2
2023
entrez:
1
7
2022
Statut:
ppublish
Résumé
Argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP) and corticobasal degeneration are four-repeat (4R) tauopathies that develop in the presenium or later. Whether these diseases are associated with the occurrence of late-onset psychiatric disorders remains unclear. To facilitate the accumulation of clinicopathological findings regarding this issue, we here present a selected series of 11 cases that clinically developed psychotic disorder (n = 7; age at onset: 41-75 years), depressive disorder (n = 1; 49 years), bipolar disorder (n = 2; 32 and 37 years) and somatoform disorder (n = 1; 88 years), and had at least one pathological hallmark of these tauopathies. The mean age at death was 74.3 years. No case showed dementia, at least in the early stage of the course. Nine cases had AGD. Granular fuzzy astrocytes in the amygdala were noted in all AGD cases and one non-AGD case. Two AGD cases had tufted astrocytes (TAs) in the amygdala but not in the frontal cortex and striatum. Three AGD and two non-AGD cases had TAs in the frontal cortex and/or striatum but not in the amygdala. One AGD case had a small number of astrocytic plaques in the frontal cortex, striatum and globus pallidus. Only one case was diagnosed as atypical PSP according to the NINDS-PSP neuropathological criteria. No case had high-level Alzheimer's disease pathology, Lewy body disease or limbic-predominant age-related TDP-43 encephalopathy. Two cases had mild neuronal loss in the hippocampus and substantia nigra, respectively. Clinicopathological studies focusing especially on early changes of 4R tauopathies, as well as the development of surrogate markers of these diseases, may be necessary for better understanding of the pathogenic backgrounds of late-onset psychiatric disorders.
Substances chimiques
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-71Subventions
Organisme : Grants from the Zikei Institute of Psychiatry
Organisme : Japan Agency for Medical Research and Development
ID : JP21dk020704
Organisme : Japan Agency for Medical Research and Development
ID : JP21wm0425019
Informations de copyright
© 2022 Japanese Society of Neuropathology.
Références
Jablensky A. Epidemiology of schizophrenia. In: Gelder MG, Andreasen NC, López-Ibor JJ Jr, Geddes JR, (eds). New Oxford Textbook of Psychiatry, Second edn. Section 4.3.5. New York: Oxford University Press, 2009; 540-553.
Joyce PR. Epidemiology of mood disorders. In: Gelder MG, Andreasen NC, López-Ibor JJ Jr, Geddes JR, (eds). New Oxford Textbook of Psychiatry, Second Edn. Section 4.5.4. New York: Oxford University Press, 2009; 645-650.
Angst J. Course and prognosis of mood disorders. In: Gelder MG, Andreasen NC, López-Ibor JJ Jr, Geddes JR, (eds). New Oxford Textbook of Psychiatry, Second Edn. Section 4.5.4. New York: Oxford University Press, 2009; 665-669.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
Stafford J, Howard R, Dalman C, Kirkbride JB. The incidence of nonaffective, nonorganic psychotic disorders in older people: A population-based cohort study of 3 million people in Sweden. Schizophr Bull 2019; 45: 1152-1160.
Skoog I. Psychiatric epidemiology of old age: The H70 study - the NAPE lecture 2003. Acta Psychiatr Scand 2004; 109: 4-18.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-468.
McKeith IG, Ferman TJ, Thomas AJ et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020; 94: 743-755.
Braak H, Braak E. Argyrophilic grains: Characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 1987; 76: 124-127.
Ikeda K, Akiyama H, Kondo H, Haga C. A study of dementia with argyrophilic grains. Possible cytoskeletal abnormality in dendrospinal portion of neurons and oligodendroglia. Acta Neuropathol 1995; 89: 409-414.
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359.
Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015-2019.
Dickson DW, Hauw JJ, Agid Y, Litvan I. Progressive supranuclear palsy and corticobasal degeneration. In: Dickson DW, Weller RO, (eds). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Second edn. Oxford: Wiley-Blackwell Press, 2011; 135-155.
Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20-33.
Dickson DW, Bergeron C, Chin SS et al. Office of Rare Diseases of the National Institutes of Health: Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61: 935-946.
Braak H, Braak E. Argyrophilic grain disease: Frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 1998; 105: 801-819.
Respondek G, Stamelou M, Kurz C et al. The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29: 1758-1766.
Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999; 53: 795-800.
Hassan A, Whitwell JL, Boeve BF et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 2010; 16: 208-214.
Ikeda C, Yokota O, Nagao S et al. Corticobasal degeneration initially developing motor versus non-motor symptoms: A comparative clinicopathological study. Psychogeriatrics 2014; 14: 152-164.
Josephs KA, Duffy JR, Strand EA et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385-1398.
Murray R, Neumann M, Forman MS et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68: 1274-1283.
Shelley BP, Hodges JR, Kipps CM, Xuereb JH, Bak TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009; 24: 1593-1599.
Tsuchiya K, Murayama S, Mitani K et al. Constant and severe involvement of Betz cells in corticobasal degeneration is not consistent with pyramidal signs: A clinicopathological study of ten autopsy cases. Acta Neuropathol 2005; 109: 353-366.
Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
Thal DR, Rüb U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
Mirra SS, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
Montine TJ, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012; 123: 1-11.
Crary JF, Trojanowski JQ, Schneider JA et al. Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-766.
McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005; 65: 1863-1872.
Saito Y, Ruberu NN, Sawabe M et al. Staging of argyrophilic grains: An age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-918.
Cairns NJ, Bigio EH, Mackenzie IR et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007; 114: 5-22.
Mackenzie IR, Neumann M, Baborie A et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.
Lee EB, Porta S, Michael Baer G et al. Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017; 134: 65-78.
Nelson PT, Dickson DW, Trojanowski JQ et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain 2019; 142: 1503-1527.
Kovacs GG, Ferrer I, Grinberg LT et al. Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy. Acta Neuropathol 2016; 131: 87-102.
Yokota O, Tsuchiya K, Arai T et al. Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. Acta Neuropathol 2009; 117: 429-444.
Van der Auwera GA, Carneiro MO et al. From FastQ data to high confidence variant calls: The genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics 2013; 43: 11.10.1-11.10.33. https://doi.org/10.1002/0471250953.bi1110s43
Yokota O, Nagao S, Ikeda C, Miki T, Terada S, Yamada N. Argyrophilic grain disease: Pathological features and related cognitive, daily living, and behavioral dysfunctions. (in Japanese. Seishin Igaku (Clin Psychiatry) 2016; 58: 941-951.
Yokota O, Miki T, Ikeda C et al. Neuropathological comorbidity associated with argyrophilic grain disease. Neuropathology 2018; 38: 82-97.
Nagao S, Yokota O, Ikeda C et al. Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci 2014; 264: 317-331.
Togo T, Isojima D, Akatsu H et al. Clinical features of argyrophilic grain disease: A retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry 2005; 13: 1083-1091.
Asaoka T, Tsuchiya K, Fujishiro H et al. Argyrophilic grain disease with delusions and hallucinations: A pathological study. Psychogeriatrics 2010; 10: 69-76.
Nishida N, Hata Y, Yoshida K, Kinoshita K. Neuropathologic features of suicide victims who presented with acute poststroke depression: Significance of association with neurodegenerative disorders. J Neuropathol Exp Neurol 2015; 74: 401-410.
Wurm R, Klotz S, Rahimi J et al. Argyrophilic grain disease in individuals younger than 75 years: Clinical variability in an under-recognized limbic tauopathy. Eur J Neurol 2020; 27: 1856-1866.
Rodriguez RD, Suemoto CK, Molina M et al. Argyrophilic grain disease: Demographics, clinical, and neuropathological features from a large autopsy study. J Neuropathol Exp Neurol 2016; 75: 628-635.
Ječmenica-Lukić M, Pekmezović T, Petrović IN, Tomić A, Svetel M, Kostić VS. Use of the neuropsychiatric inventory to characterize the course of neuropsychiatric symptoms in progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 2018; 30: 38-44.
Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain bank. Mov Disord 2003; 18: 1018-1026.
Naasan G, Shdo SM, Rodriguez EM et al. Psychosis in neurodegenerative disease: Differential patterns of hallucination and delusion symptoms. Brain 2021; 144: 999-1012.
Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 42-49.
Schrag A, Sheikh S, Quinn NP et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25: 1077-1081.
Santangelo G, Cuoco S, Pellecchia MT, Erro R, Barone P, Picillo M. Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 2018; 265: 2602-2613.
Yoshida K, Hata Y, Kinoshita K, Takashima S, Tanaka K, Nishida N. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: A forensic autopsy series. Acta Neuropathol 2017; 133: 809-823.
Pellicano C, Assogna F, Cellupica N et al. Neuropsychiatric and cognitive profile of early Richardson's syndrome, progressive Supranuclear palsy-parkinsonism and Parkinson's disease. Parkinsonism Relat Disord 2017; 45: 50-56.
Assogna F, Pellicano C, Cravello L et al. Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. Brain Behav 2019; 9: e01448.
Painous C, Martí MJ, Simonet C et al. Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study. Parkinsonism Relat Disord 2020; 74: 67-73.
Geda YE, Boeve BF, Negash S et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007; 19: 77-80.
Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65: 717-721.
Botez G, Probst A, Ipsen S, Tolnay M. Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease. Acta Neuropathol 1999; 98: 251-256.
Kovacs GG, Xie SX, Robinson JL et al. Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathol Commun 2018; 6: 50. https://doi.org/10.1186/s40478-018-0552-y
Miki T, Yokota O, Haraguchi T et al. Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases. Brain Pathol 2020; 30: 811-830.
Ikeda C, Yokota O, Nagao S et al. The relationship between development of neuronal and astrocytic tau pathologies in subcortical nuclei and progression of argyrophilic grain disease. Brain Pathol 2016; 26: 488-505.
Tatsumi S, Mimuro M, Iwasaki Y et al. Argyrophilic grains are reliable disease-specific features of corticobasal degeneration. J Neuropathol Exp Neurol 2014; 73: 30-38.
Ling H, Kovacs GG, Vonsattel JP et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain 2016; 139: 3237-3252.